Aktienanalyse wird geladen …
REGN · NASDAQ · Pharmaceuticals · USA
796,01 $
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw., gesamt) | SBC in Stück | Rückkäufe (ca.) | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 14,34 Mrd. | 4,5 Mrd. | 41,48 $ | 108,6 Mio. | 1,2 Mio · 1,1 % | 7,7 Mio · 7,1 % | 85,4 % | 31,4 % | 37,57 $ | 9,15 $ | 3,52 $ |
| 2024 | 14,2 Mrd. | 4,41 Mrd. | 38,34 $ | 115,1 Mio. | 1,2 Mio · 1,1 % | — | 86,1 % | 31,1 % | 31,84 $ | 8,54 $ | 1,76 $ |
| 2023 | 13,12 Mrd. | 3,95 Mrd. | 34,77 $ | 113,7 Mio. | 1,1 Mio · 1 % | 0,9 Mio · 0,8 % | 86,2 % | 30,1 % | 34,08 $ | 7,78 $ | — |
| 2022 | 12,17 Mrd. | 4,34 Mrd. | 38,22 $ | 113,5 Mio. | 0,9 Mio · 0,8 % | — | 87,2 % | 35,6 % | 38,99 $ | 6,39 $ | — |
| 2021 | 16,07 Mrd. | 8,08 Mrd. | 71,97 $ | 112,2 Mio. | 0,8 Mio · 0,7 % | 3,7 Mio · 3,3 % | 84,8 % | 50,3 % | 58,19 $ | 5,36 $ | — |
| 2020 | 8,5 Mrd. | 3,51 Mrd. | 30,52 $ | 115,1 Mio. | 0,5 Mio · 0,5 % | 0 Mio · 0 % | 86,8 % | 41,4 % | 17,41 $ | 3,75 $ | — |
| Quartal | Umsatz | Nettogewinn | EPS | Aktien (verw., gesamt) | Nettomarge | FCF / Aktie |
|---|---|---|---|---|---|---|
| Q2 2026 | 4,29 Mrd. | 1,3 Mrd. | 12,23 $ | 106 Mio. | 30,2 % | 5,40 $ |
| Q1 2026 | 3,61 Mrd. | 727,2 Mio. | 6,75 $ | 107,7 Mio. | 20,2 % | 7,88 $ |
| Q4 2025 | 3,88 Mrd. | 844,6 Mio. | 7,78 $ | 107,5 Mio. | 21,7 % | 8,49 $ |
| Q3 2025 | 3,75 Mrd. | 1,46 Mrd. | 13,62 $ | 107,2 Mio. | 38,9 % | 13,22 $ |
| Q2 2025 | 3,68 Mrd. | 1,39 Mrd. | 12,81 $ | 108,6 Mio. | 37,9 % | 8,52 $ |
| Q1 2025 | 3,03 Mrd. | 808,7 Mio. | 7,27 $ | 111,2 Mio. | 26,7 % | 7,34 $ |
| Q4 2024 | 3,79 Mrd. | 917,7 Mio. | 8,45 $ | — | 24,2 % | 9,79 $ |
| Q3 2024 | 3,72 Mrd. | 1,34 Mrd. | 11,54 $ | — | 36 % | — |
Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026
Regeneron Approaching Incremental Catalysts Like Upcoming Olatorepatide Data Readout, RBC Says
Regeneron (REGN) Stock Still Looks Undervalued After A 40% Run
Regeneron Highlights EYLEA HD Momentum, Dupixent Growth and Pipeline Catalysts
Is Regeneron Stock a Bargain Below $800?
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures, and commercializes medicines for people with serious diseases. Its portfolio spans treatments in eye care, immunology, oncology, cardiovascular and metabolic disease, infectious disease, hematology, and rare disorders. The company is known for combining laboratory research, clinical development, and in-house manufacturing to advance biologic therapies and antibody-based medicines. Regeneron also works on product candidates across multiple therapeutic areas, supporting a broad drug pipeline alongside its marketed medicines. Regeneron Pharmaceuticals, Inc. plays an important role in the healthcare market through its focus on specialty therapies designed for complex and often chronic medical conditions.
WebsiteMit einem Konto testest du Glancefield Pro 3 Tage gratis und bewertest REGN und jede andere Aktie unbegrenzt.